ImmuCell (NASDAQ:ICCC) Share Price Crosses Below 200 Day Moving Average of $4.95

ImmuCell Co. (NASDAQ:ICCC)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.95 and traded as low as $4.46. ImmuCell shares last traded at $4.49, with a volume of 873 shares.

ImmuCell Price Performance

The firm has a market capitalization of $33.43 million, a P/E ratio of -8.39 and a beta of 0.58. The company has a fifty day moving average of $4.66 and a 200 day moving average of $4.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.71 and a quick ratio of 1.00.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 15.21% and a negative net margin of 18.31%. The firm had revenue of $7.26 million during the quarter.

Institutional Trading of ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Mesirow Financial Investment Management Inc. purchased a new position in shares of ImmuCell Co. (NASDAQ:ICCC) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.